While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.
The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.
The Healthy on MSN13h
New Data: Nearly 50% of Weight-Loss Drug Patients Saw Lower Consumption of This, Too"For healthcare providers, these findings suggest that anti-obesity medications may offer dual benefits," one doctor reports ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...
Zepbound, which earned the nod in November 2023 ... It earned a high-dose (HD) formulation of Eylea in 2023 that decreased ...
Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback